




SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. KIEL/02		SERIAL NO. 10/047,578							
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Kiel et al.									
				FILING DATE October 26, 2001		GROUP							
U.S. PATENT DOCUMENTS													
EXAMINER INITIAL		PATENT NUMBER							ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A.A	4	5	5	2	8	9	9	11/1985	Sunshine et al.	514	568	4/9/1984
	A.B	5	5	9	9	8	4	6	2/1997	Chopdekar et al.	514	653	6/28/1996
	A.C	6	0	3	7	3	5	8	3/2000	Gordziel	514	357	3/24/1999
	A.D	6	2	8	7	5	9	7	9/2001	Gordziel	424	464	3/12/1999
	A.E												
	A.F												
	A.G												
	A.H												
	A.I												
	A.J												
A.K													
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS													
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)						
	A.L												
	A.M												
	A.N												
	A.O												
	A.P												
	A.Q												
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)													
	A.R	Goldberg, R.I. et al., <u>Evaluation of a Prolonged Action Oral Antihistaminic Preparation as Treatment for Allergic Disorders</u> , Clinical Medicine, (Sept. 1965) pp. 1475-1478.											
	A.S	Weiler, J.M. et al., <u>Randomized, double-blind, parallel groups, placebo-controlled study of efficacy and safety of Rynatan® in the treatment of allergic rhinitis using an acute model</u> , Annals of Allergy, Vol. 64, No. 1, (Jan. 1990), pp. 63-67.											
	A.T												
EXAMINER 					DATE CONSIDERED 2-4-03								
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.													

Substitute Disclosure Form (PTO-1449)

RECEIVED

MAY 01 2002

TECH CENTER 1600/2900